Indevus gets approvable letter

Indevus got a preliminary FDA nod on Valstar, its bladder cancer therapy. The drug had been taken off the market in 2002 because of "impurities" in the original formula; since then, the company has revamped its process. In May, Indevus submitted a chemistry, manufacturing, and controls supplement to the agency.

The FDA's new approvable letter blesses the chemistry portion of the app and asks for more info about manufacturing. Company officials say they'll answer within two months, and that they expect to re-introduce VALSTAR late this year or early next. 

- check out the release

Related Articles:
Indevus in $120M deal to acquire Valera. Report
Indevus halts research on pagoclone for PE. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.